CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response. - Wikidata - wikimedia - TriplyDB

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

http://www.wikidata.org/entity/Q33809161

about

Natural Killer Cells: Angels and Devils for Immunotherapy.Many si/shRNAs can kill cancer cells by targeting multiple survival genes through an off-target mechanism Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.New Advances and Challenges of Targeting Cancer Stem Cells.Identification of Differentially Expressed Genes between Original Breast Cancer and Xenograft Using Machine Learning Algorithms.Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia

P2860

Q41661175-F6A48CF1-2D2C-403D-A049-736442559699 Q42637848-17BC8A71-4A9F-4107-83DF-E7747E035C4A Q47304779-B619B5EE-65D0-43DB-BE98-6CEE78ECBDC5 Q48588244-186A5D74-D2D8-4B88-9389-FA1228675B38 Q52657721-ECB225A6-A53A-4903-835E-D68D3BD5E0CD Q58729482-960EFFDD-5175-4112-8BBA-5A55E0CDBE18 Q58749358-8A1A34AB-A37B-4B6D-A9BB-4E7EFFA7680F

P2860

CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

http://www.wikidata.org/entity/Q33809161

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.

@ast

CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.

@en

type

label

CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.

@ast

CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.

@en

prefLabel

CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.

@ast

CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.

@en

P1433

Q33809161-E4D51EED-BC07-4C60-A5A6-1610905A0886

P1476

Q33809161-B5DF9349-C284-4FF1-914B-8F63BE8EF6C8

P2093

Q33809161-1963964E-EA1E-4167-B7C4-55E02133519C

Q33809161-1D11AB84-8075-40EC-A00C-FCAE8A563B72

Q33809161-20DCC82F-255C-4F81-BD3B-15D34BE0D7B7

Q33809161-25A123C3-52C3-4FDD-A60D-1A2F1B8DC19A

Q33809161-3362C162-7074-4DB4-8B61-0C8F4B7298DE

Q33809161-6246B004-B12C-4CFE-977B-4B5B45EBB8BF

Q33809161-6613BE84-48F2-4316-9860-D099E03C827A

Q33809161-68B61DC7-FD0E-404B-A5FD-34593B5ADCC8

Q33809161-721F6473-6AB9-4E2E-AC25-6C9409C68D0F

Q33809161-797A6623-1E45-4A85-A013-A21F7E97E8B1

P2860

Q33809161-08130931-A3C0-4D55-B22A-42FDFCC55564

Q33809161-0A631897-8D3B-4E8C-91DF-55485E875687

Q33809161-0ADDEF9D-09C8-4252-B6D7-849D86383582

Q33809161-1E4C58FE-278B-4872-8ADA-E02F36F3BD04

Q33809161-272ECF90-C666-4339-87A4-20C4759F9494

Q33809161-327861B3-2F3D-4E6D-9927-AD74EE9A50CC

Q33809161-463BAAAF-5A85-4FA9-B0FE-4983EE270286

Q33809161-5394BF28-04B4-4D08-98DD-6F8F69303D76

Q33809161-54204884-D4F4-4AC0-900C-7D37557E47FF

Q33809161-573D9C62-7F03-43F4-8244-8493CE458A3A

P304

Q33809161-94FB21F4-A309-4A76-8516-8BB79888DA01

P31

Q33809161-3254C73C-54D1-4A6A-8E0F-D4DF2374934C

P356

Q33809161-6F1D46A1-32D1-41AB-874F-20269DA6831E

P433

Q33809161-D7612FEA-034B-439F-936B-DED44F494263

P478

Q33809161-7C02B830-7498-4B95-94AD-3F0CEF732101

P50

Q33809161-46C8F2CD-1C22-43E6-A447-363F4D0DAD16

P577

Q33809161-2CB14B94-5E78-41CC-A86C-8EBE7D6AAB3C

P698

Q33809161-B995F561-FC8A-496F-A939-278CF7AB0553

P932

Q33809161-BD3681C1-8B26-46F7-9701-EE6CAEFA68B6

P356

J.CELREP.2017.02.037

P1433

P1476

CD95/Fas Increases Stemness in ...... nt Type I Interferon Response.

@en

P2093

Abdul S Qadir

http://www.w3.org/2001/XMLSchema#string

Andrea E Murmann

http://www.w3.org/2001/XMLSchema#string

Arthur R Salomon

http://www.w3.org/2001/XMLSchema#string

Calvin Law

http://www.w3.org/2001/XMLSchema#string

Huiping Liu

http://www.w3.org/2001/XMLSchema#string

Jindan Yu

http://www.w3.org/2001/XMLSchema#string

Jonathan C Zhao

http://www.w3.org/2001/XMLSchema#string

Jung Kim

http://www.w3.org/2001/XMLSchema#string

Liang Mu

http://www.w3.org/2001/XMLSchema#string

Nikolai N Khodarev

http://www.w3.org/2001/XMLSchema#string

P2860

Yes and PI3K bind CD95 to signal invasion of glioblastoma

Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids

CD95 promotes tumour growth

A diverse range of gene products are effectors of the type I interferon antiviral response

Protein ISGylation modulates the JAK-STAT signaling pathway

CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells

Normal hemostasis but defective hematopoietic response to growth factors in mice deficient in phospholipid scramblase 1

Mechanisms of type-I- and type-II-interferon-mediated signalling

Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation

Stats: transcriptional control and biological impact

P304

2373-2386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2017.02.037

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P50

Marcus E. Peter

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28273453

http://www.w3.org/2001/XMLSchema#string

P932

5474321

http://www.w3.org/2001/XMLSchema#string